A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

NCT06207175 | Unknown Phase 3

• 1 other identifier: KLWS-V502-05
• Study Type: interventional
• Target: 1,260
• Locations: 1 country
• Sites: 1

Brief Summary

This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female Participants Aged 18 to 45 Years

Conditions

Human Papillomavirus Infection

Keywords

Human Papillomavirus

Outcome Measures

Primary Outcomes (2)

• Geometric mean titer (GMT) for anti-HPV neutralizing antibodies 30 days after full vaccination

  Geometric mean titer (GMT) for anti-HPV type 6/11/16/18/31/33/45/52/58 neutralizing antibodies (pseudo-virus neutralizing assay) 30 days after full vaccination in participants who are seronegative to the relevant HPV type prior to 1st vaccination.

  30 days after full vaccination

• Seroconversion Rate (SCR) for anti-HPV neutralizing antibodies 30 days after full vaccination

  Seroconversion Rate (SCR) for anti-HPV type 6/11/16/18/31/33/45/52/58 neutralizing antibodies (pseudo-virus neutralizing assay) 30 days after full vaccination in participants who are seronegative to the relevant HPV type prior to 1st vaccination.

  30 days after full vaccination

Secondary Outcomes (7)

• Geometric mean titer (GMT) of anti-HPV immunoglobulin G antibodies 30 days after full vaccination

  30 days after full vaccination

• Seroconversion Rate (SCR) of anti-HPV immunoglobulin G antibodies 30 days after full vaccination

  30 days after full vaccination

• Geometric mean titer (GMT) of anti-HPV neutralizing antibodies and immunoglobulin G antibodies 6,12,18 months after full vaccination

  6 months, 12 months and 18 months after full vaccination

• Seroconversion Rate (SCR) of anti-HPV neutralizing antibodies and immunoglobulin G antibodies 6,12,18 months after full vaccination

  6 months, 12 months and 18 months after full vaccination

• Incidenct, severity and duration of each solicited (local and systemic) AE within 7 days after each dose of vaccination

  0-7 days after each dose of vaccination

Study Arms (2)

Nonavalent HPV study vaccine

EXPERIMENTAL

Study vaccine: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) (Hereinafter referred to as "Nonavalent HPV study vaccine") Provided by: Beijing Health Guard Biotechnology, Inc. Dosage: 0.5 mL per dose Appearance: White, cloudy liquid suspension Dosage form: 0.5-mL suspension for injection as a prefilled syringe Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm Vaccination schedule in this study：3 injections on a 0, 2, 6-month schedule.

Biological: Nonavalent HPV study vaccine

GARDASIL® 9

ACTIVE COMPARATOR

Control vaccine: GARDASIL® 9 Manufacturer: Merck Sharp and Dohme Corp (MSD). Dosage: 0.5 mL per dose Appearance: After thorough agitation, GARDASIL® 9 is a white cloudy liquid Dosage form: 0.5-mL suspension for injection as a prefilled syringe Route of administration: Intramuscular injection into the lateral deltoid muscle of the upper arm Vaccination schedule：3 injections on a 0, 2, 6-month schedule.

Biological: GARDASIL® 9

Interventions

Nonavalent HPV study vaccine BIOLOGICAL

A 3-dose regimen administered at months 0, 2 and 6.

Also known as: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)

Nonavalent HPV study vaccine

GARDASIL® 9 BIOLOGICAL

A 3-dose regimen administered at months 0, 2 and 6.

GARDASIL® 9

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \*Healthy female participants, aged between 18 years and 45 years as of the 1st dose of vaccination (18 years ≤ age \< 46 years).
• Prior to enrolment, written informed consent obtained from the participants.
• \*Participants must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 14 days prior to 1st vaccination, and agree to continue such precautions for 1 month after full vaccination.
• \[Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.\]; Women of Childbearing Potential participants have a negative urine pregnancy test before the 1st dose.
• Participants are able to comply with study protocol, including all scheduled visits, vaccinations, laboratory tests, and other study procedures.
• Note: For items with an asterisk (\*), If the subject does not meet the criteria, the visit may be rescheduled when the criteria are met.

You may not qualify if:

• \* Participant has fever (axillary temperature ≥ 37.3℃) within 24 hours prior to the 1st dose of vaccination;
• Participant has vaccinated previously or plans to vaccinate with other HPV vaccines during the study period;
• Participant is participating or plans to participate in other clinical studies during the period of this study;
• Participant has a history of a positive test for HPV, or a history of an abnormal Pap test result showing atypical squamous cells - undetermined significance (ASC-US), atypical squamous cells - cannot exclude HSIL (ASC-H), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), or atypical glandular cells. Participant has a history of an abnormal cervical biopsy result showing cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ or cervical cancer;
• Participant has a history of HPV-related genital diseases (e.g., genital warts, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, vulvar cancer, vaginal cancer or anal cancer), a history of venereal disease (e.g., syphilis, gonorrhea, genital chlamydial infection, genital herpes, chancroid, lymphogranuloma venereum, inguinal granuloma, etc.);
• Participant has a history of allergy to any component of the study vaccine or severe allergic reaction to vaccine (including but not limited to anaphylaxis, allergic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction), severe urticaria, dyspnea, angioneurotic edema, etc.);
• Immunocompromised participant or participant that has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition;
• Participant who has/had epilepsy, excluding a history of febrile seizures under 2 years of age, or alcoholic epilepsy within 3 years prior to alcohol withdrawal;
• Participant who has severe liver and kidney disease, severe cardiovascular disease, severe diabetes, malignant tumors, severe infectious diseases (e.g., tuberculosis, chronic hepatitis B/C, syphilis, etc.), is unsuitable to participate in this study based on the investigator's judgement;
• Participant who has thrombocytopenia or any coagulopathy that is not suitable for intramuscular injection;
• Asplenia or functional asplenia, complete or partial splenectomy from any cause;
• Participant who is receiving or has received prolonged use (\>14 days) of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, topical medications such as ointments, eye drops, inhalants or nasal sprays are permitted) within 6 months prior to the 1st dose of vaccination, or plans to receive them during the period from 1st dose of vaccination to 30 days after full vaccination;
• Participant has received immunoglobulin or other blood products within 3 months prior to the 1st dose of vaccination or plans to receive them during the period from the 1st dose of vaccination to 30 days after full vaccination;
• \*Participant who has acute illness or in acute exacerbation of chronic diseases or use antipyretic, analgesic and anti-allergic drugs (e.g., paracetamol, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days prior to vaccination;
• \*Participant who has vaccinated with inactivated/recombinant/nucleic acid vaccines (non-attenuated vaccines) within 14 days before enrollment or attenuated vaccines within 28 days before enrollment, or plans to administrate vaccine(s) from the 1st dose of vaccination to 30 days after the full vaccination of investigational vaccine.

Sponsors & Collaborators

• Beijing Health Guard Biotechnology, Inc: lead
• University of Muhammadiyah Malang Hospital: collaborator
• Dr. M Djamil Hospital, Padang: collaborator

Study Sites (1)

University of Muhammadiyah Malang Hospital

Malang, Indonesia

Location

MeSH Terms

Conditions

Papillomavirus Infections

Interventions

Papillomavirus Vaccines; Vaccines

Condition Hierarchy (Ancestors)

Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Communicable Diseases; Infections; DNA Virus Infections; Virus Diseases; Tumor Virus Infections; Genital Diseases; Urogenital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Viral Vaccines; Biological Products; Complex Mixtures

Study Officials

• Yu Hongyang

  Beijing Health Guard Biotechnology, Inc

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: The Sponsor, investigators and biostatisticians will remain blinded to subject allocation
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2024
• First Posted: January 16, 2024
• Study Start: November 21, 2023
• Primary Completion: November 17, 2024
• Study Completion: January 25, 2026
• Last Updated: January 23, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)